CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / SMMT (SMMT) / ivonescimab
Forward catalyst · SMMT

ivonescimab

Sponsor SMMT · listed as SMMT

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ivonescimab is a clinical-stage drug asset sponsored by SMMT, listed as SMMT. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT06767527. The asset is in Phase 3 and currently recruiting, studied in Triple-Negative Breast Cancer (TNBC). It appears across 9 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06767527
PhasePHASE3
StatusRECRUITING
Lead sponsorAkeso
Listed asSMMT
Condition(s)Triple-Negative Breast Cancer (TNBC)

All tracked catalysts for ivonescimab

DateEventConfidenceTrial
2026-12-31READOUTmediumNCT06767527
2027-01-13READOUTmediumNCT06951503
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More SMMT catalysts